textabstractThis thesis includes phase I clinical and pharmacological studies on second and third generation topoisomerase I inhibitors, either administered orally, or intravenously as a macromolecular drug-delivery system, and on the antimicrotubulin agent, paclitaxel encapsulated in liposomes, to investigate the suitability of prolonged exposure of these anti-cancer agents and formulations. These studies were performed since in preclinical models, the cytotoxicity of both topoisomerase I inhibitors and paclitaxel increases with duration of exposure